Suppr超能文献

G 蛋白偶联受体的异源二聚化:与神经疾病和神经治疗学的相关性。

Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.

机构信息

Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA.

出版信息

CNS Neurol Disord Drug Targets. 2010 Nov;9(5):636-50. doi: 10.2174/187152710793361586.

Abstract

Because G protein-coupled receptors (GPCRs) are numerous, widely expressed and involved in major physiological responses, they represent a relevant therapeutic target for drug discovery, particularly regarding pharmacological treatments of neurological disorders. Among the biological phenomena regulating receptor function, GPCR heteromerization is an important emerging area of interest and investigation. There is increasing evidence showing that heteromerization contributes to the pharmacological heterogeneity of GPCRs by modulating receptor ontogeny, activation and recycling. Although in many cases the physiological relevance of receptor heteromerization has not been fully established, the unique pharmacological and functional properties of heteromers are likely to lead to new strategies in clinical medicine. This review describes the main GPCR heteromers and their implications for major neurological disorders such as Parkinson's disease, schizophrenia and addiction. A better understanding of molecular mechanisms underlying drug interactions related to the targeting of receptor heteromers could provide more specific and efficient therapeutic agents for the treatment of brain diseases.

摘要

由于 G 蛋白偶联受体 (GPCR) 数量众多、广泛表达,并参与主要的生理反应,因此它们是药物发现的相关治疗靶点,特别是在治疗神经紊乱的药理学方面。在调节受体功能的生物学现象中,GPCR 异源二聚化是一个备受关注和研究的新兴领域。越来越多的证据表明,异源二聚化通过调节受体的发生、激活和回收,有助于 GPCR 的药理学异质性。尽管在许多情况下,受体异源二聚化的生理相关性尚未完全确立,但异源二聚体的独特药理学和功能特性可能会为临床医学带来新的策略。本文综述了主要的 GPCR 异源二聚体及其在帕金森病、精神分裂症和成瘾等主要神经紊乱中的作用。更好地理解与靶向受体异源二聚体相关的药物相互作用的分子机制,可能为治疗脑部疾病提供更特异和有效的治疗药物。

相似文献

1
Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.
CNS Neurol Disord Drug Targets. 2010 Nov;9(5):636-50. doi: 10.2174/187152710793361586.
2
Receptor heteromerization and drug discovery.
Trends Pharmacol Sci. 2010 Mar;31(3):124-30. doi: 10.1016/j.tips.2009.11.008. Epub 2010 Jan 7.
3
History and biological significance of GPCR heteromerization in the neuroendocrine system.
Neuroendocrinology. 2012;95(3):223-31. doi: 10.1159/000330000. Epub 2011 Dec 9.
4
Exploring a role for heteromerization in GPCR signalling specificity.
Biochem J. 2011 Jan 1;433(1):11-8. doi: 10.1042/BJ20100458.
5
Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?
Br J Pharmacol. 2010 Jun;160(3):454-66. doi: 10.1111/j.1476-5381.2010.00777.x.
6
Understanding the role of heteroreceptor complexes in the central nervous system.
Curr Protein Pept Sci. 2014;15(7):647. doi: 10.2174/138920371507140916122738.
7
G Protein-Coupled Receptor Heteromers.
Annu Rev Pharmacol Toxicol. 2016;56:403-25. doi: 10.1146/annurev-pharmtox-011613-135952. Epub 2015 Oct 22.
8
Shaky ground - The nature of metastable GPCR signalling complexes.
Neuropharmacology. 2019 Jul 1;152:4-14. doi: 10.1016/j.neuropharm.2019.01.018. Epub 2019 Jan 17.
9
Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target.
ACS Chem Neurosci. 2019 Jan 16;10(1):190-200. doi: 10.1021/acschemneuro.8b00572. Epub 2018 Dec 20.
10
Arrestin recruitment and signaling by G protein-coupled receptor heteromers.
Neuropharmacology. 2019 Jul 1;152:15-21. doi: 10.1016/j.neuropharm.2018.11.010. Epub 2018 Nov 9.

引用本文的文献

1
Growth hormone secretagogue receptor and cannabinoid receptor type 1 intersection in the mouse brain.
Brain Struct Funct. 2024 Dec 19;230(1):15. doi: 10.1007/s00429-024-02876-3.
6
G Protein-Coupled Receptor Heteromers as Putative Pharmacotherapeutic Targets in Autism.
Front Cell Neurosci. 2020 Oct 30;14:588662. doi: 10.3389/fncel.2020.588662. eCollection 2020.
7
Role of Somatostatin in the Regulation of Central and Peripheral Factors of Satiety and Obesity.
Int J Mol Sci. 2020 Apr 7;21(7):2568. doi: 10.3390/ijms21072568.
8
Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?
Front Mol Neurosci. 2019 Oct 18;12:255. doi: 10.3389/fnmol.2019.00255. eCollection 2019.

本文引用的文献

1
Time-resolved FRET between GPCR ligands reveals oligomers in native tissues.
Nat Chem Biol. 2010 Aug;6(8):587-94. doi: 10.1038/nchembio.396. Epub 2010 Jul 11.
2
Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processes.
Curr Opin Pharmacol. 2010 Feb;10(1):59-66. doi: 10.1016/j.coph.2009.10.003. Epub 2009 Nov 5.
3
Receptor-receptor interactions: A novel concept in brain integration.
Prog Neurobiol. 2010 Feb 9;90(2):157-75. doi: 10.1016/j.pneurobio.2009.10.004. Epub 2009 Oct 20.
4
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.
J Neurochem. 2009 Dec;111(6):1478-89. doi: 10.1111/j.1471-4159.2009.06425.x. Epub 2009 Oct 8.
5
G-protein-coupled receptor oligomers: two or more for what? Lessons from mGlu and GABAB receptors.
J Physiol. 2009 Nov 15;587(Pt 22):5337-44. doi: 10.1113/jphysiol.2009.179978. Epub 2009 Sep 1.
7
Group II metabotropic glutamate receptors and schizophrenia.
Cell Mol Life Sci. 2009 Dec;66(23):3777-85. doi: 10.1007/s00018-009-0130-3. Epub 2009 Aug 26.
8
GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers?
Pharmacol Ther. 2009 Nov;124(2):248-57. doi: 10.1016/j.pharmthera.2009.07.005. Epub 2009 Aug 5.
10
Interactions between calmodulin, adenosine A2A, and dopamine D2 receptors.
J Biol Chem. 2009 Oct 9;284(41):28058-28068. doi: 10.1074/jbc.M109.034231. Epub 2009 Jul 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验